NASDAQ:REGN Regeneron Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $595.40 +4.27 (+0.72%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$586.17▼$597.0050-Day Range$548.35▼$692.8052-Week Range$538.01▼$747.42Volume386,957 shsAverage Volume721,253 shsMarket Capitalization$64.62 billionP/E Ratio8.43Dividend YieldN/APrice Target$707.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingModerate Buy2.58 Rating ScoreUpside/Downside18.8% Upside$707.43 Price TargetShort InterestHealthy2.38% of Shares Sold ShortDividend StrengthN/ASustainability-2.41Upright™ Environmental ScoreNews Sentiment0.50Based on 9 Articles This WeekInsider TradingSelling Shares$10.15 M Sold Last QuarterProj. Earnings Growth5.59%From $40.63 to $42.90 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.29 out of 5 starsMedical Sector97th out of 1,429 stocksPharmaceutical Preparations Industry37th out of 682 stocks 3.3 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 13 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $707.43, Regeneron Pharmaceuticals has a forecasted upside of 18.8% from its current price of $595.40.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.38% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 23.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 53.12% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Anakinra" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.41. Previous Next 1.4 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 21 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -48% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,148,585.00 in company stock.Percentage Held by Insiders10.76% of the stock of Regeneron Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.83% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.59% in the coming year, from $40.63 to $42.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 8.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 47.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 8.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 42.02.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Regeneron Pharmaceuticals (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock News HeadlinesJune 30, 2022 | finance.yahoo.comRegeneron (REGN) Eylea sBLA for Extended Regimen AcceptedJune 29, 2022 | markets.businessinsider.comRegeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA ReviewJune 29, 2022 | marketwatch.comRegeneron: FDA to Review Extended Eylea Regimen in Diabetic Retinopathy >REGNJune 29, 2022 | seekingalpha.comFDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindnessJune 29, 2022 | finance.yahoo.comEYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA ReviewJune 28, 2022 | rttnews.comBiotech Stocks Facing FDA Decision In July 2022 June 26, 2022 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by StockNews.com to "Hold"June 22, 2022 | americanbankingnews.comEvercore ISI Analysts Give Regeneron Pharmaceuticals (NASDAQ:REGN) a $635.00 Price TargetJune 21, 2022 | americanbankingnews.comJefferies Financial Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to SellJune 20, 2022 | finance.yahoo.comRegeneron (REGN) Moves 4.4% Higher: Will This Strength Last?June 18, 2022 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by StockNews.comJune 16, 2022 | finance.yahoo.comRegeneron (REGN) Stock Moves -0.79%: What You Should KnowJune 14, 2022 | seekingalpha.comRegeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees10,368Year Founded1988Company Calendar Last Earnings5/04/2022Today7/02/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$707.43 High Stock Price Forecast$844.00 Low Stock Price Forecast$536.00 Forecasted Upside/Downside+18.8%Consensus RatingModerate Buy Rating Score (0-4)2.57894736842105 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$70.599990 Trailing P/E Ratio8.43 Forward P/E Ratio14.65 P/E Growth1.88Net Income$8.08 billion Net Margins48.06% Pretax Margin55.33% Return on Equity50.10% Return on Assets36.73% Debt Debt-to-Equity Ratio0.14 Current Ratio4.76 Quick Ratio4.09 Sales & Book Value Annual Sales$16.07 billion Price / Sales4.02 Cash Flow$78.55 per share Price / Cash Flow7.58 Book Value$172.92 per share Price / Book3.44Miscellaneous Outstanding Shares108,539,000Free Float96,860,000Market Cap$64.62 billion OptionableOptionable Beta0.25 Social Links Regeneron Pharmaceuticals Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Regeneron Pharmaceuticals stock. View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price forecast for 2022? 19 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their REGN stock forecasts range from $536.00 to $844.00. On average, they predict Regeneron Pharmaceuticals' share price to reach $707.43 in the next year. This suggests a possible upside of 18.8% from the stock's current price. View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Regeneron Pharmaceuticals' stock price performed in 2022? Regeneron Pharmaceuticals' stock was trading at $631.52 on January 1st, 2022. Since then, REGN shares have decreased by 5.7% and is now trading at $595.40. View the best growth stocks for 2022 here. When is Regeneron Pharmaceuticals' next earnings date? Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Regeneron Pharmaceuticals. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported $11.49 EPS for the quarter, beating analysts' consensus estimates of $9.37 by $2.12. The biopharmaceutical company earned $2.97 billion during the quarter, compared to analyst estimates of $2.69 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 50.10% and a net margin of 48.06%. The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $10.09 earnings per share. View Regeneron Pharmaceuticals' earnings history. Who are Regeneron Pharmaceuticals' key executives? Regeneron Pharmaceuticals' management team includes the following people: Dr. Leonard S. Schleifer M.D., Ph.D., Founder, Pres, CEO & Director (Age 69, Pay $6.47M)Dr. George D. Yancopoulos M.D., Ph.D., Scientific Founder, Pres, Chief Scientific Officer & Director (Age 62, Pay $6.4M) (LinkedIn Profile)Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 58, Pay $1.9M) (LinkedIn Profile)Mr. Joseph J. LaRosa, Exec. VP, Gen. Counsel & Sec. (Age 63, Pay $1.75M) (LinkedIn Profile)Dr. Andrew J. Murphy Ph.D., Exec. VP of Research (Age 63, Pay $1.57M)Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 49, Pay $1.77M)Ms. Patrice Gilooly, Sr. VP of Quality Assurance & OperationsMr. Christopher R. Fenimore, Sr. VP, Head of Accounting & Controller (Age 51) (LinkedIn Profile)Mr. Gerald Underwood, Sr. VP of Technical OperationsMr. Bob McCowan, Sr. VP of IT & Chief Information Officer What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees. Who are some of Regeneron Pharmaceuticals' key competitors? Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of REGN's competitors. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $595.40. How much money does Regeneron Pharmaceuticals make? Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $64.62 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $70.599990 on an earnings per share basis. How many employees does Regeneron Pharmaceuticals have? Regeneron Pharmaceuticals employs 10,368 workers across the globe. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More When was Regeneron Pharmaceuticals founded? Regeneron Pharmaceuticals was founded in 1988. How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for Regeneron Pharmaceuticals is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at [email protected], or via fax at 914-347-2113. This page (NASDAQ:REGN) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
